Swiss Neuroendocrine Tumor (SwissNET) registry: Results after 30 Months Abstract #170

Introduction: The Swiss registry for NETs (SwissNET) was established in 2008 to improve epidemiological data on NET patients in Switzerland. Here the results after 30 months of follow-up are presented.
Aim(s): To systematically and prospectively collect relevant information of patients with NETs in Switzerland, based on a histologically confirmed diagnosis.
Materials and methods: After having obtained patient consent, contributing centers are visited by a study nurse, patient files are analysed and data are transferred into the database with disagreements resolved by a member of the SwissNET board. Inclusion criteria encompass NETs of gastrointestinal and pulmonary origin (typical and atypical pulmonary carcinoid).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christoph Stettler

To read results and conclusion, please login ...

Further abstracts you may be interested in

#397 Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
Introduction: To improve epidemiological data on patients with neuroendocrine tumors (NETs) in Switzerland, the Swiss registry for NETs (SwissNET) was established in 2008. Here we present the current state of the registry in 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Christoph Stettler
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Diego Carrillo
#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili
#2895 Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center
Introduction: Well-differentiated Neuroendocrine Pulmonary Tumors (NETp) are morphologically classified as Typical (TC) and Atypical Carcinoid (AC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hugo Tanaka